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A 53-year-old female never-smoker presented with back pain and dyspnea. Computed tomography revealed a 
right upper-lobe mass, mediastinal lymphadenopathy, peri-
cardial effusion, and a thoracic epidural soft-tissue mass. The 
patient underwent corpectomy of the epidural mass and surgi-
cal pathology revealed that this was a keratinizing squamous 
cell carcinoma (SCC), cytokeratin (CK)5/6+, p63+, thyroid 
transcription factor 1 (TTF1)− (Fig 1A). Subsequently, the 
patient underwent a pericardiocentesis, and cytology from the 
pericardial fluid showed an adenocarcinoma (ADC), CK7+, 
TTF1+ (Fig 1B). There was insufficient material for molecu-
lar testing of ADC, thus the SCC surgical specimen was evalu-
ated for epidermal growth factor receptor (EGFR) mutations, 
which revealed that the SCC harbored a L858R mutation in 
exon 21 of the EGFR gene (Fig 2A). Subsequently, the peri-
cardial effusion cytology was also evaluated and demonstrated 
a very low positive signal for the L858R mutation, but this 
was below the limit of detection of the assay, given that the 
sample contained less than 3% neoplastic cells.
The second patient is a 61-year-old female never-
smoker who presented with right supraclavicular and hilar 
masses and a malignant pleural effusion. A core needle biopsy 
of the supraclavicular mass revealed an SCC (Fig. 1C) and 
subsequent cytologic evaluation of the pleural fluid revealed 
an ADC, TTF1+ (Fig 1D). Molecular testing of the supracla-
vicular SCC and the pleural ADC specimens revealed that 
these were both positive for an EGFR exon 19 deletion of 
15 base pair (Fig 2B). Both patients were initiated on single-
agent erlotinib, and imaging studies after 2 months of therapy 
demonstrated significant tumor response in the pulmonary 
lesions and in the metastatic sites. After 4 months of therapy, 
the imaging studies of the first patient demonstrated stable 
disease whereas the second patient continued to demonstrate 
further partial response.
DISCUSSION
We present two cases of adenosquamous lung can-
cer (ADSCC) in never-smokers, which initially presented as 
pure SCC in the metastatic site. These patients were initially 
thought to have two synchronous malignancies, given the dis-
tinct histologic subtypes at different disease sites. However, 
molecular profiling revealed that both the ADC and SCC 
tumor samples harbored the same EGFR mutation, indicating 
that these likely arose from the same original malignant clone. 
EGFR mutations occur rarely in SCC with reported frequency 
of less than 5%,1 thus routine molecular testing is not usually 
recommended for SCC histology.2 In contrast, several studies 
have reported the presence of EGFR mutations in ADSCC, 
especially among never-smokers.3 Other molecular abnormal-
ities, including an ALK rearrangement in ADSCC have been 
reported.4 ADSCC comprises approximately 1% to 2% of all 
non–small-cell lung cancers and the current World Health 
Organization definition of ADSCC requires at least 10% SCC 
and ADC by light microscopy.5 However, the abovementioned 
cases demonstrate that ADSCC may present as pure SCC, 
even in large surgical specimens. One other study has reported 
the presence of EGFR mutations in SCC specimens that were 
later found to be ADSCC on further pathologic evaluation,6 
which indicates that this is a clinically significant occurrence 
that warrants attention. This case report demonstrates that a 
biopsy of SCC in never-smokers should raise the suspicion of 
an ADSCC and illustrates the importance of molecular testing 
of non–small-cell lung cancers in never-smokers regardless of 
the histological subtype to provide the optimal therapy in this 
patient population.
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FIGURE 1.  Representative hema-
toxylin and eosin stained sections 
of SCC and ADC tumors from each 
case. A, Case 1: epidural mass (SCC), 
(B) case 1: pericardial fluid (ADC), (C) 
case 2: supraclavicular mass (SCC), 
and (D) case 2: pleural fluid (ADC). 
SCC, squamous cell carcinoma; ADC, 
adenocarcinoma.
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FIGURE 2.  Molecular testing results. A, An EGFR L858R muta-
tion was identified in the SCC in patient 1 by melting curve 
analysis with a mutation-specific probe (black trace, small peak 
at ~63°C). B, A 15-base pair EGFR exon 19 deletion was identi-
fied in the SCC of patient 2 by capillary electrophoresis (peaks 
at ~102 base pair). Adenocarcinoma lesions from each patient 
shared the same EGFR mutation as the SCC component (data 
not shown). SCC, squamous cell carcinoma.
